As Cubicin Threats Line Up, Cubist Spells Out A Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm seeks new indications, late-stage assets.
You may also be interested in...
Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy
Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.
Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy
Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.
Optimer Looks To Partner C. Diff Candidate After Trial Success
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.